Exenatide
Exenatide (Byetta/Bydureon) was the first GLP-1 receptor agonist approved, derived from Gila monster saliva (exendin-4). Available in twice-daily and once-weekly formulations, it remains relevant for specific patient populations.
Evidence Summary
Exenatide has a mature, two-track evidence base. In type 2 diabetes, the EXSCEL cardiovascular outcomes trial (NEJM, 2017; n=14,752, median 3.2 years) established cardiovascular safety - major adverse cardiovascular events did not differ from placebo (HR 0.91, 95% CI 0.83-1.00; non-inferior for safety, not superior for efficacy) - alongside modest weight loss (about 2-4 kg). The most important recent development is in neurology. GLP-1 receptors are expressed in the brain, and a small 2017 phase 2 trial had suggested exenatide might slow Parkinson's disease (a 3.5-point motor advantage vs placebo). The definitive phase 3 Exenatide-PD3 trial (Lancet, 2025; 194 participants, 96 weeks) did not replicate this: off-medication MDS-UPDRS Part III scores worsened by 5.7 points on exenatide versus 4.5 on placebo (adjusted difference 0.92 points, 95% CI -1.56 to 3.39; p=0.47), with no benefit on any secondary measure. Exenatide was safe and well tolerated. Recent meta-analyses are mixed - one 2025 review of 5 RCTs found a small motor benefit (-2.06 points), another found none - so a disease-modifying role for GLP-1 agonists in Parkinson's remains unproven.
Evidence Scale
Mechanism of Action
Synthetic version of exendin-4, a peptide found in Gila monster venom with 53% homology to human GLP-1. Activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. Resistant to DPP-4 degradation. GLP-1 receptors are also expressed in neurons, which is the rationale for investigating exenatide as a potential neuroprotective (disease-modifying) agent in Parkinson's and Alzheimer's disease.
Who Is This For?
Type 2 diabetes where cost is primary concern. Patients needing postprandial glucose control specifically. Step therapy requirements before newer agents.
Protocol & Dosing
Dose
Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily, 60 min before meals. Bydureon: 2mg once weekly, any time of day regardless of meals.
Frequency
Twice daily or weekly injection
Duration
Ongoing
Protocol Summary
First-generation GLP-1 RA. Twice-daily formulation (Byetta) requires timing with meals. Extended-release (Bydureon) offers weekly convenience. Least potent but most affordable option in the class.
Interactions & Precautions
Contraindications
- Severe renal impairment (CrCl <30)
- Medullary thyroid carcinoma history
- MEN2
- Severe GI disease
Potential Risks
- •Injection site reactions with extended-release
- •Higher immunogenicity than human-analog GLP-1 RAs
- •Thyroid tumor risk
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Consider as cost-effective entry point to GLP-1 therapy. Higher nausea rates than newer agents. Anti-drug antibodies may reduce efficacy over time. Renal dose adjustment needed. Most patients will benefit from upgrading to semaglutide or tirzepatide. On the neurology question: despite promising phase 2 data, the definitive phase 3 Exenatide-PD3 trial (2025) found no disease-modifying benefit in Parkinson's disease. Exenatide is not indicated for neurological conditions, and this remains an area of research rather than practice.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Latest Evidence
2024-2026: the phase 3 verdict on exenatide and Parkinson's
Exenatide was the first GLP-1 receptor agonist, and for a decade its most exciting prospect was neurological rather than metabolic. A small 2017 single-centre phase 2 trial (Lancet; 62 patients, 60 weeks) hinted that once-weekly exenatide might slow Parkinson's disease - off-medication motor scores showed a 3.5-point advantage over placebo (p=0.0318). That signal drove a wave of interest in GLP-1 agonists as potential disease-modifying therapies for neurodegeneration.
The definitive test has now reported. The phase 3 Exenatide-PD3 trial (Lancet, 2025) randomised 194 people with Parkinson's across six UK centres to extended-release exenatide 2 mg once weekly or placebo for 96 weeks. It found no disease-modifying benefit: off-medication MDS-UPDRS Part III scores worsened by 5.7 points on exenatide versus 4.5 on placebo (adjusted difference 0.92 points, 95% CI -1.56 to 3.39; p=0.47), with no advantage on any secondary measure - though the drug was safe and well tolerated. Recent meta-analyses are split: a 2025 review of 5 RCTs found a small motor benefit (-2.06 points, 95% CI -4.09 to -0.03) while another found none. The question is not fully closed, but the largest and most rigorous trial to date is clearly negative. In type 2 diabetes, exenatide's established role is unchanged - EXSCEL (NEJM, 2017; 14,752 patients) confirmed cardiovascular safety without superiority.
Exenatide is approved for type 2 diabetes, not for Parkinson's or any neurological condition; the neurology findings above are research results, most of them negative. These are summaries of published research, not treatment claims. Educational information, not medical advice - discuss any GLP-1 therapy with a qualified clinician.
Exenatide in Parkinson's disease · phase 2 (2017) vs phase 3 (2025)
Why the phase 3 trial reversed the early optimism
Lower (more negative) scores mean less motor disability. In the 2017 single-centre phase 2 trial (n=62, 60 weeks) exenatide-treated motor scores improved by 1.0 point while placebo worsened by 2.1 points - an adjusted 3.5-point advantage (p=0.0318). The larger, multicentre phase 3 Exenatide-PD3 trial (n=194, 96 weeks) did not replicate this: both groups worsened similarly (exenatide +5.7 vs placebo +4.5; adjusted difference 0.92 points, 95% CI -1.56 to 3.39; p=0.47). Sources: Athauda et al., Lancet (2017) and Vijiaratnam et al., Lancet (2025). Exenatide is not approved for Parkinson's disease. Educational summary of published research, not a treatment claim.
Related on Peak Human
Liraglutide
The GLP-1 with the most-studied brain-health readouts to date.
Semaglutide
The once-weekly GLP-1 with greater weight loss and glucose control.
Dulaglutide
Once-weekly GLP-1 with outcomes-proven cardiovascular benefit.
Retatrutide
Investigational triple agonist - the most potent incretin in trials.
GLP-1 Agonists
How the GLP-1 class compares, side by side.
Metformin
Foundational metabolic-longevity agent, often paired with GLP-1s.
Oral GLP-1
A GLP-1 option in the shop, via an independent third-party supplier.
Optimization at Peak Human
Physician-supervised, biomarker-tracked optimization programs.
Longevity Research Insider
Weekly review of new longevity research.
Key references: Exenatide once a week versus placebo as a potential disease-modifying treatment for Parkinson's disease (Exenatide-PD3) - The Lancet (2025) · Exenatide once weekly versus placebo in Parkinson's disease: a phase 2 randomised controlled trial - The Lancet (2017) · GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis - Therapeutic Advances in Neurological Disorders (2025) · Evaluating the neuroprotective effect of GLP-1 receptor agonists in Parkinson's disease: a systematic review & meta-analysis - Neurological Sciences (2025) · Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL) - New England Journal of Medicine (2017)
Cost & Access
Cost Range
$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
